The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review

Laura Evangelista1 · Pietro Zucchetta1 · Lucia Moletta2 · Simone Serafini2 · Gianluca Cassarino1 · Nicola Pegoraro1 · Francesca Bergamo3 · Cosimo Sperti2 · Diego Cecchin1

Received: 17 March 2021 / Accepted: 11 May 2021 / Published online: 28 May 2021
© The Author(s) 2021

Abstract
The aim of the present systematic review is to examine the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) associated with computed tomography (CT) or magnetic resonance imaging (MRI) in assessing response to preoperative chemotherapy or chemoradiotherapy (CRT) for patients with borderline and resectable pancreatic ductal adenocarcinoma (PDAC). Three researchers ran a database query in PubMed, Web of Science and EMBASE. The total number of patients considered was 488. The most often used parameters of response to therapy were the reductions in the maximum standardized uptake value (SUVmax) or the peak standardized uptake lean mass (SULpeak). Patients whose SUVs were higher at the baseline (before CRT) were associated with a better response to therapy and a better overall survival. SUVs remaining high after neoadjuvant therapy correlated with a poor prognosis. Available data indicate that FDG PET/CT or PET/MRI can be useful for predicting and assessing response to CRT in patients with resectable or borderline PDAC.

Keywords Pancreatic cancer · FDG · Neoadjuvant therapy · PET/CT · PET/MRI

Introduction
Pancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis. Survival rates are very low, ranging from 20 to 5% after 1–5 years for all stages combined [1]. The proportion of PDAC resectable at the time of diagnosis is approximately 20–30% [2]. In cases of locally advanced cancer with borderline resectability, stereotactic body radiotherapy and concurrent chemotherapy might increase the chances of curative surgery, thereby improving prognosis [3]. Assessing response to therapy is sometimes difficult with the usual morphological imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) because they are unable to distinguish persistent tumor from postoperative or post-radiation changes [4]. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) can be used to measure the tumor’s metabolic rate before and after treatment, contributing to an assessment of the efficacy of combined therapies. Hybrid PET/CT scanners have already been employed to measure response to neoadjuvant therapy in a number of solid tumors [5]. Some experiences are now available for PDAC too [6]. The aim of the present systematic review is to investigate the role of FDG PET/CT or PET/MRI in assessing response to preoperative chemotherapy or chemoradiotherapy (CRT) in patients with borderline or resectable PDAC.

Materials and methods
Literature search
A systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA). Three researchers (L.E.,
G.C., N.P.) ran queries in the PubMed, Web of Science and EMBASE databases to retrieve prospective or retrospective studies on the use of FDG PET/CT or PET/MRI for assessing response to therapy in patients with borderline and resectable PDAC.

The following search strings were used “FDG” AND “PET” AND “pancreatic cancer”, “FDG PET/CT” AND “pancreatic cancer”, “PET” AND “pancreatic cancer”, “PET/CT” AND “pancreatic cancer”, “PET” AND “pancreatic cancer” and “neoadjuvant”, “FDG PET” AND “pancreatic cancer” and “neoadjuvant”, “PET” AND “FDG” AND “pancreatic cancer” AND “response to therapy”, and “FDG PET/CT” AND “pancreatic cancer” AND “response to therapy”. No date limits or language restriction were applied. The literature search was up to date as of 1 January 2021. After excluding duplicates, case reports, case series and review articles, the titles and abstracts of the records retrieved were carefully examined. Full texts of the selected articles were obtained, and those written in the English language were carefully analyzed. The following criteria were used to select the studies of interest: (1) FDG was used as a radiopharmaceutical agent, (2) more than 10 patients were enrolled, (3) patients with resectable PDAC were involved, (4) hybrid imaging (PET/CT or PET/MRI) was used for diagnostic purposes, and (5) baseline and post-treatment PET/CT scans were available. The references in the articles selected were also screened for additional studies.

Data extraction

The following data were extracted for each article: authors, year of publication, study design, number of patients enrolled, type of neoadjuvant therapy regimen, number of PET/CT or PET/MRI scans, intervals between PET scans and therapy, and details of the image acquisition protocol and the criteria used to assess response to neoadjuvant therapy.

Quality assessment of studies

The methodological quality of the studies was judged by two investigators (L.E and G.C.) using the “Quality Assessment of Diagnostic Accuracy Studies” tool, v. 2 (QUADAS-2) [7].

Results

From a total of 84 papers identified in the databases, 49 studies were eligible after excluding any duplicates. Then further selection led to the retrieval of 27 full texts, but only 11 studies met our inclusion criteria for the present review (Fig. 1).

Based on the QUADAS-2, most of these papers have a low risk of bias and applicability issues. A few papers revealed some unclear data concerning the reference standards used and patient selection, as shown in Fig. 2.

Table 1 lists the characteristics of the studies selected [8–18]. The total number of patients enrolled was 488. Four of the 11 studies (36%) were prospective. In all cases, at least 2 PET/CT or PET/MRI scans had been obtained, one before and one after therapy [8–14, 16–18]. Zimmerman et al. [15] reported on 3 PET/CT scans obtained before, during and after CRT. In 6 studies, a combined therapy was used to treat borderline or resectable PDAC [8, 11, 12, 14–16, 18]. PET/MRI was only used in one study [18].

Table 2 shows methodological details for the studies considered. The most often used parameters of response to therapy were the reduction in the maximum standardized uptake value (SUV) or the peak standardized uptake lean mass (SUL) [8–16, 18]. In particular, reductions in SUV max [or the regression index (RI)] of more than 50% were associated with a more favorable response to therapy than in the case of smaller reductions [8, 10, 11, 14, 15, 18]. In two studies, changes in metabolic volume parameters or other specific criteria (i.e., PET response criteria in solid tumors—PERCIST or SUV max × blood glucose level/100−SUV gluc) were also used to assess response to neoadjuvant therapy [13, 16], demonstrating the additional value of alternative PET metrics in predicting and assessing response to therapy.

Some authors wrote that patients with higher baseline (pre-CRT) SUVs were associated with a better response to therapy [8], and a better overall survival (OS) [14]. SUVs remaining high after neoadjuvant therapy correlated with a poor prognosis [12]. In addition to the absolute SUVs before and after therapy, many authors found the RI useful for assessing response to therapy [8, 10, 11] for the purposes of selecting candidates suitable for subsequent resections. Associating changes in SUV max with other PET measurements—such as metabolic tumor volume (MTV), total lesion glycolysis (TLG) or SUL peak—could improve the prediction of response to treatment and OS [18]. Barnes et al. [14] found that PET data in association with carbohydrate antigen 19–9 (CA 19–9) levels could significantly predict outcome and response to CRT, though Panda et al. [18] reported that CA 19–9 levels showed some limitations in predicting OS.

In contrast with the above-mentioned findings, Barbour et al. [17] reported that SUV max did not predict outcome or response to therapy, and Zimmerman et al. [15] only found a trend toward a predictive value for response to neoadjuvant therapy on FDG PET. That said, Barbour et al. [17] had acquired PET images very soon (only 15 days) after starting neoadjuvant CRT, and Zimmerman et al. [15] had enrolled only a very limited number of patients (n = 15) in the context of a clinical trial.

Dalah et al. [13] found that 15% of patients had progressive disease when using PERCIST criteria, as opposed to only 7% when they applied response evaluation criteria in
solid tumors version 1.1 (RECIST1.1). In other words, PERCIST appears to increase the chances of detecting patients with progressive disease. Yokose et al. [16] also aimed to confirm the usefulness of PERCIST for assessing the effect of treatment based on the pathological response to treatment, and to examine the prognostic utility of FDG PET/CT parameters. They confirmed that PERCIST and SUVmax were superior to RECIST for the purpose of assessing the effects of preoperative treatment.

Zimmermann et al. [15] examined the prognostic value of FDG PET and diffusion-weighted MRI (DWI) obtained before and then twice during neoadjuvant treatment. FDG PET/CT identified responders and non-responders more accurately than the mean apparent diffusion coefficient (ADC). Panda et al. [18] also showed that hybrid PET/MRI can help ascertain pathological response to therapy in PDAC with a high negative predictive value.

Table 3 summarizes the major findings in terms of the surgical outcomes and the consistency between findings on histopathology and imaging. The complete resection (R0) rate ranged between 64 and 100% of the population studied. The rate of responders to neoadjuvant therapy exceeded 50% in 5 studies [8, 9, 11, 16, 17]. Based on a semiquantitative score (the RI), the consistency between histopathology and FDG PET data was reportedly in the ranges of 67–93% for responders, and 53–74% for non-responders.
Discussion

The present systematic review raises some points worth discussing. First, a high SUV\textsubscript{max} on baseline PET scans in patients with resectable or borderline PDAC is associated with a better response to neoadjuvant CRT. Although it is often associated with a more aggressive disease than in the case of tumors with a lower SUV, a rapid cancer cell proliferation rate is associated with a greater chemosensitivity and radiosensitivity. The choice of an appropriate treatment regimen depends on tumor stage, and also on certain other biological and genetic predictors, and a high baseline SUV in patients with resectable or borderline primary PDAC could be seen as an additional predictor of responsiveness and survival.

Second, cancers usually form an inhomogeneous mass with interstitial fibrosis in which the underlying structure is replaced by fibrous tissue containing a number of tumor cells [19, 20]. CRT may exacerbate their inhomogeneity as a result of its cytopathic effect, and because coagulation and or necrosis depend on blood flow and oxygenation [21]. Given these histologically diverse settings, semiquantitative PET parameters reflect the whole-lesion viability of PDAC. In a recent meta-analysis, Wang et al. [8] showed that patients with a greater reduction in SUV\textsubscript{max} after different kinds of adjuvant treatment tended to have better survival rates (HR 0.68, 95% CI, 0.47–0.98, \( p = 0.037 \)). The authors did not differentiate between neoadjuvant and adjuvant therapy; however, a careful analysis of the findings of the present review shows that a reduction in SUV in the range of 40–60% can be considered as the best cutoff for classifying response to neoadjuvant CRT in patients with resectable or borderline PDAC (see Table 2). The association between reductions in MTV and TLG can further reinforce the final assessment of the efficacy of therapy, and correlation with CA 19–9 levels seems too. Little evidence is available as yet, however, on the prognostic value of replacing reductions in SUVs with PERCIST criteria in this disease setting. Patients with favorable SUVs but less favorable RECIST criteria after preoperative treatment would proceed to resection in the hope of benefiting from surgery. Indeed, a significant reduction in SUVs after CRT was also associated with a better prognosis after a median 40–44 months of follow-up [11, 14]. On the other hand, a patient with an incomplete metabolic response or limited reduction in SUV\textsubscript{max} or SUV\textsubscript{gluc} on post-treatment metabolic imaging is unlikely to achieve a complete histopathological response after surgery. These patients might benefit from further chemotherapy or a more aggressive treatment before undergoing resection (rather than immediate radical surgery) to prevent early metastatic spread. As emerged from a careful analysis of Table 3, however, many patients with a lower RI (i.e., metabolic non-responders) showed a less than 80% agreement between their RI and their histopathological findings. RI alone probably cannot be a valuable surrogate parameter for assessing response to neoadjuvant therapy in borderline resectable and locally advanced PDAC, so its association with other biological parameters is essential.

On a third point, although dynamic changes in SUV after preoperative therapy can be useful for predicting the pathological response and prognostic benefit of surgery, there are some issues with the use of FDG PET for assessing the efficacy of neoadjuvant treatment. One major problem concerns clinical conditions other than cancer that influence the SUV. For instance, radiation therapy occasionally causes acute inflammatory changes in surrounding non-cancerous tissues, giving rise to false-positive cases mainly because these inflammatory changes and the presence of metabolically active leukocytes and macrophages lead to erroneously high SUVs. The timing of FDG PET/
| No. | Author, ref | Year of pub | Country | Study design | N of pts | Chemotherapy (alone or + RT) | Chemotherapy alone | CHT and RT | Type of scanner | N of PET scans | Time among PET scan | Outcome |
|-----|-------------|-------------|---------|--------------|---------|-----------------------------|-------------------|------------|----------------|--------------|-------------------|---------|
| 1   | Kittaka et al. [8] | 2013 | Japan | R | 40 | Gemcitabine-based chemoradiotherapy | No | Yes | PET/CT | 2 | Baseline and at least 8 weeks after the completion of radiation therapy | SUV measurement by FDG PET/CT can be a useful tool to select suitable candidates for preoperative CRT and subsequent resection, predicting the locoregional effect of preoperative CRT. |
| 2   | Ielpo et al. [9] | 2016 | Spain | P | 25 | Gemcitabine and nab-paclitaxel | Yes | No | PET/CT | 2 | Baseline and pre-operative scan | SUV from FDG PET can help in defining the response to therapy. |
| 3   | Mellon et al. [10] | 2017 | USA | R | 70 | Gemcitabine or GTX or folfirinox or gem + abraxane or others | Yes | No | PET/CT | 2 | Baseline Post-CRT | Pre-operative PET/CT and CA19.9 response correlate with histopathologic tumor regression. |
| 4   | Akita et al. [11] | 2017 | Japan | R | 83 | Gemcitabine-based chemoradiotherapy | No | Yes | PET/CT | 2 | Baseline and at least 8 weeks after the completion of chemoradiation | FDG PET/CT is useful to evaluate the efficacy of pre-operative therapy for PDAC. |
| 5   | Sakane et al. [12] | 2017 | Japan | R | 25 | Gemcitabine-based chemoradiotherapy | No | Yes | PET/CT | 2 | Baseline after the completion of therapy | Higher post-treatment SULpeak and positive MTV/TLG could predict the unfavorable histopathological effects of CRT in patients with pancreatic adenocarcinoma. |
| No. | Author, ref          | Year of pub | Country | Study design | N of pts | Chemotherapy (alone or + RT) | Chemo-therapy alone | CHT and RT | Type of scanner | N of PET scans | Time among PET scan | Outcome |
|-----|----------------------|-------------|---------|--------------|----------|------------------------------|---------------------|-------------|----------------|----------------|----------------------|---------|
| 6   | Dalah et al. [13]    | 2018        | USA     | P            | 15       | Gemcitabine or xeloda and foltirinox or gemcitabine and abraxane | Yes                 | No          | PET/CT         | 2              | Baseline after 3–7 weeks from the end of chemotherapy | FDG PET can be more informative than CT for the definition of response to therapy |
| 7   | Barnes et al. [14]   | 2020        | USA     | R            | 104      | Gemcitabine-based chemoradiation or capecitabine-based chemoradiotherapy | No                  | Yes         | PET/CT         | 2              | Baseline and approximately 4 weeks following the completion of neoadjuvant therapy | CA19.9 monitoring mirrors quantitative changes in the burden of disease. SUV_{max} levels may provide complimentary information in estimating the tumor's biologic behavior |
| 8   | Zimmermann et al. [15] | 2020     | Germany | P            | 18       | Gemcitabine and oxaliplatin radio-chemotherapy | No                  | Yes         | PET/CT         | 3              | Baseline PET after two courses of NAT after 10 weeks from NAT (chemo + RT) | FDG PET/CT may be a reliable method to evaluate response to the combined therapy |
| 9   | Yokose et al. [16]   | 2020        | Japan   | R            | 22       | Gemcitabine and nab-paclitaxel or TS1 + cisplatin + mitomycin and radiotherapy | No                  | Yes         | PET/CT         | 2              | Baseline and 2–3 weeks after completion of neoadjuvant treatment | PERCIST more accurately reflected neoadjuvant treatment’s therapeutic effect on PDAC than RECIST |
| 10  | Barbour et al. [17]  | 2020        | Australia | P            | 42       | Gemcitabine and nab-gemcitabine | Yes                 | No          | PET/CT         | 2              | Baseline and after 15 days from the start of therapy | PET/CT cannot be able to detect an early response to nab-gem in patients with advanced pancreatic cancer |
CT after treatment is consequently important. In the present review, 3 studies conducted repeat (post-CRT) FDG PET/CT or PET/MRI scans less than 4 weeks after the first [14, 16, 17], while 4 studies did so more than 4 weeks after the end of CRT [8, 11, 13, 15]. Such a variability in the present literature makes it hard to say for sure, but it would seem to be best to wait at least 6 weeks after CRT before obtaining a follow-up scan. The proposal of 6 weeks can be summarized as follow. Usually, the time from the end of chemotherapy or CRT and surgery is 6 weeks, as reported in some of the selected papers [9, 15, 17]. The opportunity to make a FDG PET/CT or PET/MR scan very close to the surgical approach, after neoadjuvant therapy, would be useful. Moreover, a median time between 4 and 8 weeks would be considered enough for reducing the inflammatory processes in the surrounding tumor tissues after completion of RT.

Blood sugar levels before and after therapy may vary, particularly in patients with a low insulin production, and this can further affect SUVs.

Finally, little information is available as yet on the utility of PET/MRI for assessing response to therapy in resectable or borderline PDAC. The only published paper [18] discusses the PET metric data rather than the advantages in terms of contrast resolution offered by MRI in the integrated scanner. The role of DWI and ADC is still controversial in this setting of patients [13]. Hybrid PET/MRI scanners could facilitate the assessment of the R0 resection rate with a view to improving the complete response rate after surgery, and the OS as a consequence. Prospective trials are needed in this setting, however.

In conclusion, the available data show that PET/CT or PET/MRI with FDG have potential as tools for predicting and assessing response to CRT in patients with resectable or borderline PDAC. They can also be useful for the prognostic stratification of patients after CRT. That said, the small numbers of patients enrolled in each study, the different criteria used to assess response to therapy, and the diverse therapy regimens all go to show that more efforts are needed to conduct well-designed prospective trials.

### Table 1 (continued)

| No. | Author, ref | Year of pub | Country | Study design | N of pts | Chemotherapy (alone or + RT) | CHT and RT Type of scanner | N of PET scans | Time among PET scans | Outcome |
|-----|-------------|-------------|---------|--------------|---------|-----------------------------|---------------------------|----------------|---------------------|---------|
| 11 | Panda et al. [18] | 2020 | USA | R | 44 | Gemcitabine and oxaliplatin radio-chemotherapy | PET/MRI | 2 | Baseline and post- | Metabolic metrics from PET/MRI and morphologic metrics from CT may help assess pathologic response to NAT as well as predict survival. CA 19-9 does not correlate with the outcome |

**Definitions:**
- **CHT + RT:** Chemoradiation therapy.
- **PDAC:** Pancreatic adenocarcinoma.
- **SUL:** Standardized uptake lean.
- **MTV:** Metabolic tumor volume.
- **TLG:** Total lesion glycolysis.
| No. | Author          | No of pts | Time between administration and acquisition | Acquisition duration | Glycemia (mg/dL) | Administered FDG dose | PET criteria for the assessment of response to NAT | SUVmax median reduction (%) |
|-----|----------------|-----------|-------------------------------------------|----------------------|------------------|----------------------|------------------------------------------------|-----------------------------|
| 1   | Kittakaet al [8]| 40        | 120 min                                   | NA                   | NA               | 3.7 MBq/kg (mean dose 200 MBq) | SUVmax reduction                        | 53.0 ± 19.0 in responder 41.0 ± 12.0 in non-responder |
| 2   | Ielpo et al. [9]| 25        | NA                                        | NA                   | NA               | NA                   | SUV reduction                                | 41.8 (SUVmean 7.9 pre-neoadjuvant 4.6 post-neoadjuvant) |
| 3   | Mellon et al. [10]| 70       | > 90 min                                   | NA                   | < 200            | 3.7 MBq/kg (mean dose 200 MBq) | SUVmax reduction                        | 61.1                          |
| 4   | Akita et al. [11]| 83        | 120 min                                   | NA                   | 104 ±29.7        | 3.7 MBq/kg (mean dose 200 MBq) | SUVmax reduction                        | 44.1 ± 20.3 in poor responder 67.1 ± 15.1 in good responder |
| 5   | Sakane et al. [12]| 25       | 60 min                                    | 2 min scan/bed position × 11 positions | 72–148         | 3.7 MBq/kg            | SULpeak, SUVmax, MTV, TLG                  | 24.0–57.0 in responder 28.0–47.0 in non-responder |
| 6   | Dalah et al. [13]| 15        | 45–60 min                                  | NA                   | NA               | 10–19 mCi            | PERCIST, SULpeak                        | 44.0–53.0                     |
| 7   | Barnes et al. [14]| 104      | 60 min                                    | NA                   | < 200            | Standard dose of 370 MBq for patients weighing < 55 kg, 444 MBq for patients weighing 55–91 kg, and 518 MBq for patients weighing > 91 kg | PERCIST, SUVmax reduction |                                                   |
| 8   | Zimmermann et al. [15]| 18       | 60 min                                    | NA                   | NA               | 5 MBq/kg             | SUVmax reduction                        | 54.0 (median SUVmax decreased from 8.29 baseline to 3.83 at the end of treatment) |
| 9   | Yokose et al. [16]| 22        | 60–75 min                                  | 120 s for each bed position in the three-dimensional mode | < 200         | 4 MBq/kg             | PERCIST, SULpeak                        | 38.8                          |
| 10  | Barbour et al. [17]| 42        | NA                                        | NA                   | NA               | NA                   | No level of reduction in SUVmax from baseline was predictive of early response to therapy |                                                   |
| 11  | Panda et al. [18]| 44        | 60 min                                    | 60 min              | < 200            | 10 mCi               | SUVmax reduction and SUVcl reduction SULpeak reduction | 64% change in SUVmax 64% change in SUVcl reduction |                                                   |

NAT neoadjuvant therapy, MTV metabolic tumor volume, TLG total lesion glycolysis, NA not available, SUV standardized uptake value, SUL standardized uptake lean
Table 3 Data about surgery, histology and PET imaging in all studies

| No. | Author          | Surgical treatment | N of R₀ | Histological evaluation | PET responders | Agreement between PET findings and histology |
|-----|-----------------|--------------------|--------|-------------------------|---------------|---------------------------------------------|
| 1   | Kittaka et al. [8] | NA                | 40/40  (100%) | Response = 21 (53%)  | RI < 46% = 20 | Responders 71%                             |
|     |                 |                    |        | No response = 19 (47%) | RI > 46% = 20 | No responders = 74%                         |
| 2   | Ielpo et al. [9] | 17/25 PD = 10 DP = 4 | 17/17  (100%) | CR or near CR = 13 (76%) | NA           | NA                                         |
|     |                 | TP = 3             |        | PR = 2 (11%)            |               | NA                                         |
|     |                 |                    |        | No response = 3 (13%)   |               | NA                                         |
| 3   | Mellon et al. [10] | NA                | NA     | CR or near CR = 34 (42%) | NA           | NA                                         |
|     |                 |                    |        | PR = 37 (46%)           |               | NA                                         |
|     |                 |                    |        | No response = 10 (12%)  |               | NA                                         |
| 4   | Akita et al. [11] | PD = 47 DP = 34 TP = 2 | 83/83  (100%) | Poor response = 69 (83%) | RI < 50% = 44 | Responders 13/14 (93%)                     |
|     |                 |                    |        | Good response = 14 (17%) | RI > 50% = 39 | No responders = 43/39 (62.3%)               |
| 5   | Sakane et al. [12] | NA                | NA     | CR = 0 | RI < near PR = 17 (68%) | SULpeak reduction < 41.3 = 13 | Responders = 4/6 (67%)                     |
|     |                 |                    |        | PR = 17 (32%)           | SULpeak reduction > 41.3 = 12 | No responders = 10/19 (53%)               |
| 6   | Dalah et al. [13] | NA                | NA     | CR or near CR = 27/148 (18%) | NA           | NA                                         |
|     |                 |                    |        | PR or near PR = 121/148 (82%) |               | NA                                         |
| 7   | Barnes et al. [14] | 148/201           | 126/1 48  (85%) | Response = 16 (67%) | NA           | NA                                         |
|     |                 |                    |        | No response = 8 (33%)   |               | NA                                         |
| 8   | Zimmermann et al. [15] | In 16 pts PD = 7 DP = 7 | 12/16  (75%) | NA | RI > 30% = 15/16 | Responders 85%                             |
|     |                 | TP = 2             |        | Response = 16 (67%) | RI < 30% = 1/16 | No responders = 58.3%                     |
|     |                 |                    |        | No response = 8 (33%)   | NA           | Responders = 9/12 (75%)                   |
|     |                 |                    |        | NA |               | No responders = 5/8 (63%)                  |
| 9   | Yokose et al. [16] | NA                | 14/22  (64%) | Response = 15 (52%) | NA | Responders 9/12 (75%)                     |
|     |                 |                    |        | No response = 14 (48%)  | NA           | No responders = 5/8 (63%)                  |
| 10  | Barbour et al. [17] | NA                | 25/29  (86%) | Response = 15 (52%) | NA | Responders 9/12 (75%)                     |
|     |                 |                    |        | No response = 14 (48%)  | NA           | No responders = 5/8 (63%)                  |
| 11  | Panda et al. [18] | PD = 29 DP = 7 TP = 8 | 44/44  (100%) | CR or near CR = 19/44 (43%) | NA | Responders 9/12 (75%)                     |
|     |                 |                    |        | PR or near PR = 25/44 (57%) |               | No responders = 5/8 (63%)                  |

R₀ clear margins, NA not available, RI retention index, PD pancreatoduodenectomy, DP distal pancreatectomy, TP total pancreatectomy, CR complete response, PR partial response

Author contribution Conceptualization, L.E. and D.C.; methodology, L.E., G.C., N.P., L.M.; writing—original draft preparation, L.E., L.M., F.B.; writing—review and editing, P.Z., D.C., C.S., S.S.; visualization, C.S., D.C. All authors have read and agreed to the published version of the manuscript.

Funding Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement. This research received no external funding.

Declarations

Conflict of interest All the authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Sant M, Allemani C, Santauquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCare-4 survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009;45:931–91.

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

3. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.

4. Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zulupski MM, Shields AF. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2010;33:257–61.

5. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189–204.

6. Wang L, Dong P, Shen G, Hou S, Zhang Y, Liu X, et al. 18F-Fluorodeoxyglucose positron emission tomography predicts treatment efficacy and clinical outcome for patients with pancreatic carcinoma: a meta-analysis. Pancreas. 2019;48:996–1002.

7. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.

8. Kittaka H, Takahashi H, Ohigashi H, Gotok K, Yamada T, Tominita Y, et al. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg. 2013;37:69–78.

9. Jelpe B, Caruso R, Duran H, Diaz E, Fabra I, Malavé L, et al. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surg Oncol. 2017;26:402–10.

10. Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017;56:391–7.

11. Akita H, Takahashi H, Ohigashi H, Tomokuni A, Kobayashi S, Sugimura K, et al. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol. 2017;43:1061–7.

12. Sakane M, Tatsumi M, Hori M, Onishi H, Tsuboyama T, Nakamoto A, et al. Volumetric parameters of 2-deoxy-2-[18F]fluorodeoxyglucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma. Eur J Radiol. 2017;94:64–9.

13. Dalal E, Tai A, Oshima K, Hall WA, Erickson B, Li YA. PET-based treatment response assessment for neoadjuvant chemoradiation in pancreatic adenocarcinoma: an exploratory study. Transl Oncol. 2018;11:1104–9.

14. Barnes CA, Aldackkak M, Clarke CN, Christians KK, Bucklan D, Holt M, et al. Value of Pretreatment 18F-fluorodeoxyglucose positron emission tomography in patients with localized pancreatic cancer treated with neoadjuvant therapy. Front Oncol. 2020;10:500.

15. Zimmermann C, Distler M, Jentsch C, Blum S, Folprecht G, Zöphel K, et al. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial. PaCa-DD-041 (Eudra-CT 2009–011968-11). Strahlenther Onkol. 2021;197:19–26.

16. Yokose T, Kitago M, Matsusaka Y, Masugi Y, Shinoda M, Yagi H, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Cancer Med. 2020;9:4059–68.

17. Barbour AP, Samra JS, Haghhighi KS, Donoghoe MW, Burge M, Harris MT, et al. Australasian gastro-intestinal trials group (AGITG) GAP investigators. The AGITG GAP study: a phase ii study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer. Ann Surg Oncol. 2020;27:2506–15.

18. Panda A, Garg I, Truty MJ, Kline TL, Johnson MP, Ehman EC, et al. Borderline resectable and locally advanced pancreas cancer: FDG PET/MRI and CT tumor metrics for assessment of neoadjuvant therapy pathologic response and prediction of survival. AJR Am J Roentgenol. 2020. https://doi.org/10.2214/AJR.20.24567.

19. Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007;117:50–9.

20. Tjomsland V, Niklasson L, Sandström P, Borch K, Druid H, Bratthäll C, et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol. 2011. https://doi.org/10.1155/2011/212810.

21. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med. 2012;53:693–700.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.